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XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because1Department of Translational Medicine and Neurogenetics, Institut de Ge´ne´tiq
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bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, orue et de Biologie Mole´culaire et Cellulaire, Centre National de la Recherche
e la Recherche Me´dicale Unite´ 964, University of Strasbourg, 67404 Illkirch
Cedex 05, France; 3Laboratoire de Diagnostic Ge´ne´tique, Hoˆpitaux Univer-
y of Human Genetics. All rights reserved.
, 2013
organism levels or functional connection to the disease
(e.g., involvement in synaptic organization or plasticity).
However, functional tests showing an effect of a candidate
mutation at the protein or cellular level do not necessarily
imply that this effect is inherently responsible for the dis-
ease. Indeed, some false positives can lie in mutations that
have been ‘‘functionally’’ validated (see, for instance,
SRPX2 [MIM 300642] below).
Genetic validation of a mutation usually includes cose-
gregation analysis in the proband’s family and testing for
the absence of the mutation in a population of control
chromosomes. Cosegregation analyses that validate muta-
tions in simplex cases often lack statistical power and can
lead to misleading conclusions, even in families with
several affected individuals. Some noncausative variants
will segregate by chance with the disease only because
they lie in the linked candidate region, which often con-
tains many genes. Recently, the identification of genes
implicated in ID or autism spectrum disorders (ASDs) has
extensively relied on the detection of de novo events,
but it is clear now that such events can also be detected
in unaffected siblings and hence that the de novo criterion
is not sufficient to imply pathogenicity. Moreover, for X-
linked genes, because de novo mutations occur more often
in the male germline, probands’ mothers are often silent
carriers of a transmitted pathogenic mutation that might
have occurred de novo in preceding generations. Investi-
gating the maternal grandparents is thus very useful and
informative but is often not possible. Lastly, because of
the cost-efficiency limitations of Sanger sequencing, the
number of control individuals sequenced is often limited
to a few hundred individuals, which is therefore insuffi-
cient to allow the detection of rare innocuous variants.
Some false-positive conclusions about the involvement
of some genes in XLID might have arisen notably by the
overinterpretation of the pathogenicity of missense vari-
ants, and this might concern genes proposed for mutation
screening in XLID diagnostic panels.
A new powerful resource, the National Heart, Lung, and
Blood Institute (NHLBI) data set of over 6,500 sequenced
exomes (available on the Exome Sequencing Project
Exome Variant Server [EVS]) can now be used for ascertain-
ing the frequency of potential mutations in large cohorts
of adults initially selected for cardiac, lung, or metabolic
phenotypes but a priori not enriched with neurological
or cognitive defects. This very large project originally
aimed to identify genes underlying complex heart, lung,
and metabolic disorders and provides detailed exome-vari-
ation information on unrelated African American and Eu-
ropean American individuals (2,443 males and 4,060
females), amounting to a total of 10,563 X chromo-
somes.15 Because participants had to provide written
informed consent,16 one can expect that these cohorts
do not contain individuals with moderate or severe ID
and that even the mild form is presumably underrepre-
sented as compared to its incidence in the general popula-
tion. This cohort can hence be considered as a ‘‘generalThe Amerpopulation’’ for the analysis of rare variations in genes
with a proposed implication in ID when mutated.
List of 106 Geneswith ReportedMutations Involved in
XLID
We established a list of 106 genes proposed to be associated
with XLID by compiling data from reviews, lists of genes
proposed for XLID diagnosis, and recent primary publica-
tions (Figure 1). Two of these 106 genes (MTM1 [MIM
300415] and GJB1 [MIM 304040]) appear to be misassoci-
ated with ID, given that very few cases were reported
with both ID and centronuclear myopathy (MIM
310400) or Charcot-Marie Tooth neuropathy (MIM
302800) and that they carry deletions encompassing other
genes in addition toMTM1 orGJB1.17,18 Both genes should
thus be removed from XLID lists. For the remaining 104
genes, we systematically screened the NHLBI EVS data.
We assumed that out of the ~2,500 males of the NHLBI
population, there would be fewer than 50 males (2%)
potentially affected by ID. Consequently, a previously pub-
lished XLID mutation reported in two NHLBI males would
imply that this mutation is responsible for 4% (2/50) of all
ID cases and is therefore more common than the fragile X
expansion mutation, which is very doubtful. Such a
variant should therefore be considered a nonpathogenic
(or low penetrance) rare single-nucleotide variant (SNV)
with respect to monogenic forms of ID. The same logic
can be applied if truncating variants (nonsense and splice
variants) are identified in more than one male from the
NHLBI population in a gene associated with ID; this would
confer it a major role in ID, which is suspicious. This led us
to further assess the association between some genes and
ID when (1) truncating variants are observed in males
within the NHLBI cohort (Table S1, available online), (2)
previously described IDmutations are detected in this pop-
ulation at a frequency inconsistent with a causative effect
on cognitive impairment (Tables S2 and S3), and (3) the
implication of this gene in XLID relies on a single piece
of evidence. For all such genes, we discuss the current evi-
dence of their association with monogenic forms of ID on
the basis of both the literature and our EVS data analysis
(Supplemental Data and Table 1). All other genes were
considered to be convincingly implicated in ID.
Presence in EVS of Truncating Variants Affecting
Genes Involved in XLID
We first analyzed the NHLBI cohort data set to evaluate the
presence, notably in males, of truncating SNVs in genes
with a proposed implication in ID (Table S1). We did not
include in our analysis the small indels that have been
recently added to EVS (v.0.0.15, October 31, 2012) because
the frequency of some of them indicates that they are pre-
sumably false-positive observations, either due to artifacts
inherent from the sequencing technology or to difficulties
in reliably annotating small indels (Table S4).70 For
instance, the frameshift c.1777_1780del (p.Leu593Phefs*
7) has been reported in NLGN4X (MIM 300427) in 20ican Journal of Human Genetics 93, 368–383, August 8, 2013 369
Figure 1. Representation along the X Chromosome of the 106 Genes in which Mutations Have Been Reported in XLID and Classifi-
cation According to Both the Type and Number of Mutations Reported in OMIM
Genes for which involvement in XLID is convincing are listed on the left side of the chromosome, and genes for which implication in ID
either is questionable or needs to be replicated are listed on the right side of the chromosome.GJB1 andMTM1 are linked to diseases with
no real ID association and are thus not included in the figure. The color code was designed according to the total number of mutations
reported in OMIM. If at least one truncating mutation (splice mutations, nonsense mutations, frameshifts, and large deletions that
(legend continued on next page)
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homozygous females but only in a single heterozygous
one, which departs from Hardy-Weinberg equilibrium. A
total of 21 truncating SNVs are present in EVS and are
distributed among 15 of the 104 genes in the XLID list (Ta-
ble S1). Truncating variants found at the heterozygous
state in females are not inconsistent with an implication
of these genes in XLID. Similarly, hemizygous truncating
variants that affect only some specific splicing isoforms
do not question the implication of such genes either.
When a unique truncating variant affecting the main iso-
form of a gene is identified in a single male (such as one
in MAGT1 [MIM 300715], ZNF41 [MIM 314995], ZNF81
[MIM 314998], or ATP6AP2 [MIM 300556]), the interpreta-
tion is more ambiguous, and this alone cannot rule out
the gene’s role in ID. However, two different truncating
variants have been reported in NXF5 (MIM 300319) in
eight males and in ZNF674 (MIM 300573) in 19 males,
and this seriously challenges the implication of these genes
in monogenic XLID (see below and Supplemental Data).
Presence in EVS of Known XLID Mutations
We then investigated the presence among the NHLBI
cohort of all XLID mutations identified in the 104 genes,
which are listed in OMIM or were retrieved by a PubMed
search (Table S2), and we found 22 such mutations (Table
S3). All but two (c.1186C>T [p.Pro396Ser] in CASK and
c.217C>T [p.Leu73Phe] in PTCHD1, identified in single
heterozygous females) were detected in both males and fe-
males and are probably noncausative variants instead of
real disease-causing mutations. The majority of these
missense mutations (16/20) that now appear to be innoc-
uous variants are predicted to have benign or unknown
consequences on protein function. The pathogenicity of
some of these missense mutations (c.515C>A [p.Pro172-
His] in TSPAN7, c.3872C>T [p.Pro1291Leu] in FLNA, and
three missense mutations in DMD) was already questioned
by the authors.71–73 Concerning the FGD1 (MIM 300546;
involved in Aarskog-Scott syndrome [AAS (MIM
305400)]) c.935C>T (p.Pro312Leu) mutation, which was
detected twice in NHLBI males, the phenotype of the re-
ported family did not fit with classical AAS, already sug-
gesting that it might not be a truly pathogenic muta-
tion.74 Even more surprising was the identification of 18
males carrying NDUFA1 mutation c.94G>C (p.Gly32Arg),
which was demonstrated to have functional consequences
on protein activity.75,76 Such observations question these
specific mutations, but they do not raise doubt about the
involvement of the cognate genes in ID given that several
other convincing mutations have been reported in such
genes (TSPAN7 [MIM 300096], FLNA [MIM 300017],might encompass several exons) was described, genes are in red (mo
total), or green (only one mutation). If only missense mutations or
are in violet (more than five mutations in total), blue (two to five m
genes discussed in this paper but whose implication in ID remains v
gene is included (abbreviations are as follows: L, Lubs4; R, Ropers8; G,
Ambry Genetics). References for the genes not reported in any list are
Huang et al., and [5] Witham et al.
The AmerFGD1, NDUFA1 [MIM 300078], and PDHA1 [MIM
300502]). However, for other genes (SRPX2, ZNF41, ARH-
GEF6 [MIM 300267], etc.), the presence of mutations at a
relatively high frequency in the general population chal-
lenges their involvement in ID (see the following sections
and Table 1).
Questioning Monogenic Involvement of 28 Specific
Genes in XLID
Our investigation focused on 28 genes proposed to play a
role in XLID when mutated and for which there is a
paucity of confirmatory studies or some contradictory ele-
ments arising from the analysis of the EVS data (Table 1).
This allowed us to classify them into five categories. We
highlight five genes that appear very unlikely to play a
role in ID with high penetrance in males (AGTR2 [MIM
300034], MAGT1, NXF5, ZNF674, and ZNF41; we refer to
these as ‘‘highly questionable’’) and five others for which
implication in ID appears suspicious (ZNF81, ARHGEF6,
ATP6AP2, SRPX2, and ZCCHC12 [SIZN1, MIM 300701];
we refer to these as ‘‘questionable’’). For 15 genes, addi-
tional confirmation studies are required, but no contradic-
tory findings were found in EVS. These include some genes
that have never been replicated since their first publication
more than 8 years ago (IGBP1 [MIM 300139], KIAA2022
[MIM 300524], KLF8 [MIM 300286], NLGN3 [MIM
300336], ZDHHC15 [MIM 300576], ZMYM3 [MIM
300061], and MAOA [MIM 309850]; we call these ‘‘never
replicated’’) or others that have been recently described
but have not yet been replicated (CCDC22 [MIM
300859], CLIC2 [MIM 300138], CNKSR2 [MIM 300724],
FRMPD4 [MIM 300838], HCFC1 [MIM 300019], NAA10
[MIM 300013], RPL10 [MIM 312173], and SHROOM4
[MIM 300579]; we refer to these as ‘‘awaiting replication’’).
Finally, for three genes—HUWE1 (MIM 300697), PTCHD1,
and SYN1 (MIM 313440)—our analysis and/or recent
confirmation reports support a real implication in ID (we
refer to these genes as ‘‘likely’’). We detail here current ar-
guments and evidence for the five highly questionable
genes and also present a few others as examples of the
four other categories (SRPX2 and ARHGEF6 as question-
able,MAOA as never replicated, HCFC1 as awaiting replica-
tion, and HUWE1 as likely). The detailed information for
the remaining 18 genes is given in the Supplemental Data.
AGTR2: Highly Questionable
After a de novo balanced (X;7)(q24;q22) translocation dis-
rupting AGTR2 (angiotensin II receptor 2) was identified in
one female with ID, it was screened in a cohort of 590 male
ID probands, 38 of whom were in families affected byre than five mutations in total), orange (two to five mutations in
mutations involved in expression decrease were identified, genes
utations in total), or purple (only one mutation). Asterisks denote
ery likely. In parentheses next to each gene are lists in which that
Greenwood Genetic Center; E, Emory Genetics Laboratory; and A,
as follows: [1] Honda et al., [2] Houge et al., [3] Voineagu et al., [4]
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Table 1. List of All 28 Genes Discussed and Associated Evidence Supporting or Questioning Their Involvement in ID
Gene (RefSeq
Accession Number) Listsa
Reason
for
Highlightb
Identification
Methodc ID Structural Variations ID Point Mutations
Occurrence
of Mutations
in EVSd
Truncated
Variants
in EVS
dN/dS Ratio
(#N/#S)
Protein
Size
Implication
in ID
AGTR2
(NM_000686.4)
L, R, G, E,
A
T 1 (X; 7) translocation in a
female19
c.402del (p.Phe134Leufs*5)19 (see Table S4) yes (1 F) 0.731 (19/8) 363 highly
questionable
(already
controversial)20–22
c.62G>T (p.Gly21Val)19,23 10 M, 23 F (htz)
c.971G>A (p.Arg324Gln)19 4 M, 24 F (htz)
c.1009A>G (p.Ile337Val)19 NF
c.157A>T (p.Ile53Phe)24 NF
c.572G>A (p.Gly191Glu)23 NF
MAGT1 (IAP)
(NM_032121.5)
L, R, G, E T 3 - c.1028T>G
(p.Val311_343Gly)25
5 M, 8 F (htz) yes (1 M) 0.453 (15/10) 367 highly
questionable
NXF5
(NM_032946.2)
L, R, G, A T 1 inv(X)(p21.1;q22) in two
males;26,27 deletion
disrupting the NXF
cluster;28,29 duplication at
Xq22.1 disrupting30 and
duplicating31 NXF5 in
one female and one male,
respectively
- - yes (8 M) 0.783 (30/11) 365 highly
questionable
ZNF674
(NM_001039891.2)
L, R, E, A T 1 deletion encompassing
ZNF673, ZNF674, RP2,
SLC9Z7, and CHST7 in
one male;32 duplication
encompassing ZNF673,
ZNF674, and CHST733
c.352G>T
(p.Glu118*)32
NF yes (19 M) 0.750 (28/10) 581 highly
questionable
(already
controversial)34c.1235C>A (p.Pro412Leu)
32 NF
c.1028C>T (p.Met343Thr)32 49 M, 16 F (hmz),
223 F (htz)
ZNF41
(NM_007130.2)
L, R, G, E,
A
M 1 (X; 7) translocation
disrupting ZNF4135
c.332C>T (p.Pro111Leu)35
c.7342A>C (p.?)35
2 M, 8 F (htz) yes (1 M, 1 F) 0.696 (45/17) 779 highly
questionable
5 M, 9 F (htz)
ZNF81
(NM_007137.3)
L, R, G, E,
A
M 1 (X; 9) translocation in
one female;36 1.3 Mb
duplication
encompassing >30 genes
at Xp11.23–p11.3
in one male;37 335 kb
microduplication bearing
two other genes at
Xp11.2–p11.3 in one
male38
c.536G>A
(p.Ser179Asn)36
NF yes (1 M) 0.595 (25/11) 661 questionable
ARHGEF6
(NM_004840.2)
L, R, G, E,
A
M 1 (X; 21) translocation
in one male39
c.16611T>C (p.?)39 5 M, 13 F (htz) no 0.456 (28/18) 776 questionable
ATP6AP2
(NM_005765.2)
L, R, G, E,
A
T 2 - c.321C>T
(p.Asp107Asp)
(affects splicing)40
NF yes (1 M) 0.444 (14/10) 350 questionable
(Continued on next page)
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Table 1. Continued
SRPX2
(NM_014467.2)
L, R, G, E,
A
M 2 - c.980A>G (p.Asn327Ser)41 3 M, 8 F (htz) no 0.728 (31/14) 465 questionable
c.215A>C (p.Tyr72Ser)41 1 M
ZCCHC12 (SIZN1)
(NM_173798.2)
E M 3 - c.19C>T (p.Arg7Cys)42 5 M, 28 F (htz) no 0.406 (19/14) 402 questionable
c.1031C>T (p.Thr344Ile)42 NF
IGBP1
(NM_001551.2)
L, G, E I 2 - 50 UTR 2 bp substitution
affecting IGBP1 expression43
not covered no 0.487 (19/11) 339 never replicated
KIAA2022
(NM_001008537.2)
L, R, G, E,
A
I 1 inv(X)(q13;p22)
in two related males44
- NA no 0.441 (54/34) 1,516 never replicated
KLF8
(NM_007250.4)
L, R, G, E I 1 (X; 21) translocation
leading to a loss of KLF8
expression in a woman45
- NA no 0.831 (16/6) 359 never replicated
NLGN3
(NM_181303.1)
L, R, G, E,
A
I 3 - c.1411C>T
(p.Arg451_471Cys) in
two ASD brothers46
NF no 0.209 (17/27) 848 never replicated
ZDHHC15
(NM_144969.2)
L, G, E I 1 (X; 15) translocation
leading to a loss of
ZDHHC15 expression
in a female47
- NA no 0.628 (17/8) 337 never replicated
ZNF261 (ZMYM3)
(NM_201599.2)
R I 1 (X; 13) translocation
disrupting ZMYM3 in
one female48
- NA no 0.232 (31/42) 1,370 never replicated
MAOA
(NM_000240.3)
L, R, G, E,
A
I 1 MAOA-MAOB-NDP
deletion in subjects
with severe ID49
c.886C>T (p.Gln296*)50 NF no 0,359 (14/12) 527 never replicated
CCDC22
(NM_014008.3)
- I 3 - c.49A>G (p.Thr17Ala)51 NF no 0.809 (40/17) 627 awaiting
replication
CLIC2
(NM_001289.4)
- I 4 - c.303C>G
(p.His101Gln)52
NF no 0.346 (6/5) 247 awaiting
replication
CNKSR2
(NM_014927.3)
- I 1 partial deletion of
CNKSR253
- NA no 0.340 (22/19) 1,034 awaiting
replication
FRMPD4
(NM_014728.3)
- I 1 partial duplication of
FRMPD454
- NA no 0.383 (57/46) 1,322 awaiting
replication
HCFC1
(NM_005334.2)
- I 2 - chrX: 152890455A>G55 NA no 0.227 (50/80) 2,035 awaiting
replication
c.674G>A (p.Ser225Asn)55 NF
NAA10
(NM_003491.2)
L I 4 - c.109T>C (p.Ser37Pro)56 NF no 0.074 (2/8) 235 likely in Ogden
syndrome but
needs further
replication in
nonsyndromic ID
c.346C>T (p.Arg116Trp)13 NF
(Continued on next page)
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Table 1. Continued
Gene (RefSeq
Accession Number) Listsa
Reason
for
Highlightb
Identification
Methodc ID Structural Variations ID Point Mutations
Occurrence
of Mutations
in EVSd
Truncated
Variants
in EVS
dN/dS Ratio
(#N/#S)
Protein
Size
Implication
in ID
RPL10
(NM_006013.3)
L, R, G, E,
A
I 3 - c.616C>A (p.Leu206Met)
(ASD)57
NF no 0.154 (2/4) 214 awaiting
replication
c.639C>G (p.His213Gln)
(ASD)57,58
NF
SHROOM4
(NM_020717.3)
L, R, G, E,
A
I 1 X-autosome translocations
in two females;59 Xp11.22
deletion bearing SHROOM4
in one family54
c.3266C>T (p.Ser1089Leu)59 NF yes (1 F) 0.918 (86/28) 1,493 awaiting
replication
c.1422A>G (p.Glu474Glu)59 NF
HUWE1
(NM_031407.5)
L, R, G, E,
A
I 1 microduplications
encompassing HSD17B10
and HUWE160,61 or
HUWE1 alone62 in a total
of 16 unrelated families
c.12037C>T
(p.Arg4013Trp)61
NF no 0.201 (67/105) 4,374 likely
c.8942G>A (p.Arg2981His)61 NF
c.12559C>T
(p.Arg4187Cys)61
NF
c.2849T>A (p.Val950Asp)
(ASD)63
NF
PTCHD1
(NM_173495.2)
L M 1 160 kb deletion leading
to a null PTCHD1 in
dizygotic ASD twin
brothers;64 50–390 kb
inherited deletions
disrupting PTCHD1 in
six ASD male probands;65
90 kb deletion disrupting
PTCHD1 in three related
ID males;60,66 200 kb
deletion in two ID
brothers67
c.517A>G (p.Ile173Val)66 2 M, 2 F (htz) no 0.366 (29/25) 888 likely
c.583G>A (p.Val195Ile)66 NF
c.1008_1009delinsTA
(p.MetLeu336_337IleIle)66
NF
c.217C>T (p.Leu73Phe)66 1 F (htz)
c.1436A>G (p.Glu479Gly)66 NF
c.1409C>A (p.Ala470Asp)66 NF
c.1076A>G (p.His359Arg)66 NF
SYN 1
(NM_006950.3)
L, R, G, E,
A
M 2 - c.1067G>A (p.Trp356*)68 NF no 0.347 (12/12) 705 likely
c.1663C>T (p.Gln555*)69 not covered
c.152C>G (p.Ala51Gly)69 11 M, 30 F (htz)
c.1648G>A (p.Ala550Thr)69 not covered
c.1699A>G (p.Thr567Ala)69 not covered
Abbreviations are as follows: L, Lubs et al.;4 R, Ropers et al.;8 G, Greenwood Genetic Center (see Web Resources); E, Emory Genetics Laboratory (see Web sources); A, Ambry Genetics (see Web Resources); T, truncating
variants reported in EVS; M, ID mutations reported in EVS; I, one piece of evidence or study implicating this gene in ID; htz, heterozygous; hmz, homozygous M, number of males carrying the mutation; F, number of females
carrying the mutation; NF, not found; NA, not applicable; N, number of nonsynonymous variants; and S, number of silent variants.
aLists in which genes are included.
bReason why we discuss this gene in the paper.
cApproach used for the initial identification, consistent with the information from the text: 1, positional candidate found through rearrangement or CNV; 2, sitional candidate located in a linked region; 3, functional candi-
date; and 4, through exome or X-exome sequencing.
dOccurrence of ID mutations in EVS.
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probable or possible XLID.19 This led to the identification
of (1) a 1 bp deletion causing a frameshift (c.402del
[p.Phe134Leufs*5]) in a family affected by probable XLID
and in another simplex case and (2) three missense muta-
tions (c.62G>T [p.Gly21Val], c.971G>A [p.Arg324Gln],
and c.1009A>G [p.Ile337Val]) absent from 510 control X
chromosomes. A further study of 57 males with ID de-
tected two individuals with the p.Gly21Val or p.Ile53Phe
changes.24 Other extensive studies (25 XLID-affected fam-
ilies showing coherent linkage to the locus, 116 affected
sibling pairs, and 224 simplex cases,9,20 as well as another
set of families10) failed to detect any additional mutations
(besides the p.Gly21Val variant and amissense variant that
did not show full cosegregation in a family that was later
shown to carry a SOX3 [MIM 313430] mutation). More
recently, screening of 203 Japanese males with ID detected
an additional inherited missense change (c.572G>A
[p.Gly191Glu]) in a boy showing severe ID, pervasive
developmental disorder, and epilepsy.23 Meanwhile, both
the p.Phe134Leufs*5 frameshift and the p.Gly21Val
variant were reported—in rarely cited publications—in
males from control cohorts, suggesting that they are un-
likely to be causative.21,22 This is now supported by the
NHLBI data, given that two of the three initially reported
missense variants (p.Gly21Val and p.Arg324Gln) are pre-
sent in ten and four males, respectively. Moreover,
although we did not include the indel data from EVS, we
noted that the initial frameshift mutation was observed
in 7 of 1,770 European American males (minor allele fre-
quency [MAF] ¼ 0.4%), but not in African American indi-
viduals, thus excluding a possible sequencing artifact
(Table S4). Consequently, EVS data support the serious
doubts previously raised about the implication of AGTR2
in ID, despite the suggestive phenotype of the AGTR2-
knockout mouse showing altered memory capacities and
abnormal dendritic-spine morphology.77
NXF5: Highly Questionable
Mutant NXF5 (nuclear RNA export factor 5) was suspected
to cause ID after pericentric inversion inv(X)(p21.1;q22),
leading to the loss of NXF5 expression, was identified in
an ID-affected male.26,27 The observation of two nonsense
variants (c.162G>T [p.Cys54*] and c.958G>A [p.Arg320*])
affecting a total of eight males in EVS raises serious doubts
about the involvement of this gene in ID, despite some
indication of its function in the brain. This gene was
more recently found to be deleted or duplicated in other
ID individuals, but never alone.28,29,31
MAGT1: Highly Questionable
After the identification of an ID-causing mutation in
TUSC3 (encoding a putative subunit of an oligosaccharyl-
transferase complex [MIM 601385]), the sequencing of
its X-linked paralog gene,MAGT1 (magnesium transporter
1, formerly called IAP), in XLID-affected families revealed
one missense change segregating with the ID status (LOD
score 1.8) and absent frommore than 267 control chromo-The Amersomes.25 This variant (p.Val311Gly but annotated
c.1028T>G [p.Val343Gly] in EVS) was detected in 13 out
of 10,557 X chromosomes from the NHLBI cohort. More-
over, one male from the same population carries a
nonsense variant in this gene. Although the implication
of TUSC3 in recessive ID appears well supported from the
identification of additional consanguineous families
affected by mutations in this gene,78 no ID-related muta-
tion has been reported in MAGT1 since 2008, and its
disruption has been recently associated with several forms
of X-linked immunodeficiency without neurological man-
ifestations.79 In light of these observations, there is no cur-
rent support for the implication of MAGT1 in ID.
ZNF674: Highly Questionable
After the identification of one ID-associated CNV encom-
passing ZNF674 (zinc-finger protein 674) and four other
genes (RP2 [MIM 300757], SLC9A7 [MIM 300368],
CHST7 [MIM 300375] and ZNF673 [MIM 300585]), its
screening in additional families led to the identification
of a nonsense mutation (c.352G>T [p.Glu118*]) segre-
gating with the ID phenotype in a large family (LOD score
2.51).32 Further screening of 28 families with nonsyn-
dromic XLID exhibiting coherent linkage to the region
and 309 simplex cases detected one inherited missense
change (c.1235C>A [p.Pro412Leu]) in two related males
and a second (c.1028C>T [p.Thr343Met]) in another small
family.32 Males carrying the p.Pro412Leu missense variant
also displayed partial trisomy 21 and monosomy 18 as a
result of an unbalanced translocation, which precluded
conclusions about the causative effect of this variant.
Also, the authors concluded that the p.Thr343Met
missense variant was unlikely to be pathogenic (despite
its being absent from 354 controls) because it did not affect
a highly conserved residue and because the replacing
methionine was present in the ZNF674 chimpanzee ortho-
log. EVS data indicate that this variant is present in 49
males, 223 carrier females, and 16 homozygous females,
fully excluding its implication in ID. The implication of
ZNF674 in ID was recently questioned when it was found
to be deleted together with RP2 (in retinitis pigmentosa
[MIM 312600]) in two families with X-linked retinal dys-
trophy without cognitive impairment.34 Lastly, given
that two nonsense mutations (c.1324C>A [p.Asp442*]
and c.601G>A [p.Arg201*]) have been reported in the
NHLBI cohort and that one is present in 19 hemizygous
males, ZNF674 seems unlikely to be involved in mono-
genic ID.
ZNF41: Highly Questionable
ZNF41 (zinc-finger protein 41) was found to be disrupted
by a de novo balanced (X;7) translocation in a girl with se-
vere developmental delay.35 Subsequent screening of 210
probands from families affected by probable or possible
XLID revealed one missense change (c.332C>T [p.Pro111-
Leu]) and one intronic variant (c.47942A>C) causing a
splicing alteration; both are absent from over 400 controlican Journal of Human Genetics 93, 368–383, August 8, 2013 375
X chromosomes, and both show cosegregation in the fam-
ilies. Although the authors concluded carefully that ZNF41
could be an ID candidate, it is now included inmost lists of
ID-associated genes. However, two truncating variants
have been reported in one male and one female in EVS,
and the two putative point mutations initially described
by Shoichet et al. have been detected in a total of seven
males at a frequency too high to be fully penetrant ID mu-
tations (see Table 1).35 No other ZNF41mutation has been
reported since the initial 2003 report.
SRPX2: Questionable
In 2006, Roll et al. reported a family affected by probable
dominant XLID, rolandic epilepsy, and speech dys-
praxia.41 Sequencing the genes of the linkage region
(LOD score 3.01) revealed only a missense variant
(c.980A>G [p.Asn327Ser]) in SRPX2 (sushi-repeat-contain-
ing protein, X-linked 2). Another missense variant
(c.215A>C [p.Tyr72Ser]) was detected in one epileptic
male and his female relatives, all of whom showed addi-
tional bilateral perisylvian polymicrogyria. This latter
variant was reported to increase the affinity of the encoded
SRPX2 for the urokinase-type plasminogen activator recep-
tor.80 The initial p.Asn327Ser alteration was shown to
affect protein glycosylation and to cause partial retention
of the altered protein within the endoplasmic reticulum
in a transfected-cell model.41 Despite their observed func-
tional consequences, both variants are present in EVS in
three males and eight females (all of European American
origin; p.Asn327Ser) and in onemale (p.Tyr72Ser). Accord-
ingly, 0.28% of the EVS European American population
carries one of these two variants, which considerably
weakens the evidence supporting a role for SRPX2 in epi-
lepsy, speech, and cognition. It is most unlikely that muta-
tions in SRPX2 are a major cause of epilepsy given that no
mutation has been reported in this gene since 2006,
despite its sequencing in 100 individuals with a similar
phenotype of epilepsy and speech disorder (D. Sanlaville,
G. Lesca, and P. Szepetowski, personal communication).
Because SRXP2 seems to play a role during brain develop-
ment and was recently shown to influence neuronal
migration in the developing cerebral cortex in rats (P. Sze-
petowski, personal communication), we cannot, however,
exclude that other drastic alterations of SRXP2 function
might cause cognitive impairment.
ARHGEF6: Questionable
ARHGEF6 (a-PIX or Cool-2; rho guanine nucleotide ex-
change factor 6) was identified as disrupted via an in-
herited balanced (X;21) translocation in a male with
ID.39 In the same study, subsequent screening of 119 unre-
lated males with nonsyndromic ID allowed the identifica-
tion of a cosegregating intronic mutation (c.16611T>C)
affecting splicing in a large XLID-affected family; it was ab-
sent from 170 control chromosomes. However, this in-
tronic variant has been reported in EVS in five males, all
of European origin (MAF ¼ 0.26%). An inherited duplica-376 The American Journal of Human Genetics 93, 368–383, August 8tion of ARHGEF6 was also reported in two brothers with
moderate ID, but later analysis showed that the duplica-
tion spanned 1.8 Mb and encompassed 24 genes.81,82 In
the Tarpey et al. study, twomissense changes were detected
in single families: c.362G>A (p.Arg121His), which is found
in 14 NHLBI males, and c.992A>G (p.Tyr331Cys), which is
not observed in EVS. However, the latter missense variant
is not in the list of likely pathogenic mutations and was
not further commented on by the authors. Engineered
aPix (Arhgef6)-deficient mice present altered hippocampal
neuronal connectivity, impaired synaptic function, and
additional cognitive deficits.83 However, because no other
pathogenic mutation has been described since 2003 and
given the unlikely pathogenicity of the initially reported
splice variant, the implication of ARHGEF6 in ID still re-
mains unclear.
MAOA: Never Replicated
The combined loss of MAOA (monoamine oxidase A)
and MAOB (MIM 309860), along with the deletion of the
gene associated with Norrie disease, NDP (MIM 300658),
has been described in some probands with a continuous
syndrome and presenting with severe ID.49 In 1993, Brun-
ner et al. described a large Dutch family affected by
X-linked mild ID and prominent behavioral abnormalities
associated with disturbances in monoamine metabolism
and segregating with a truncating mutation (c.886C>T
[p.Gln296*]) in MAOA.30,50 More recently, deletions of
MAOA with MAOB alone were described in two males
with severe developmental delay or ID.60,84 Mouse models
with total Maoa inactivation or with a spontaneous muta-
tion present indeed enhanced aggressive behavior and
additional ‘‘autistic-like’’ features.85 To our knowledge, no
other clearly pathogenic mutation has been reported in
MAOA in other individuals in the past 20 years,86 even
though one missense variant (c.812A>T [p.Asn271Ile])
was reported in a proband with ASD.87 However, we
recently identified a pathogenic missense mutation
(c.797_798GC>TT [p.Cys266Phe]) associated with defi-
cient MAOA activity in one family affected by autism,
ID, and abnormal behavior, confirming the findings from
1993 (A.P., unpublished data). A third family harboring a
MAOA mutation was recently identified (M. Field, J.
Gecz, and V.M. Kalscheuer, personal communication).
HCFC1: Awaiting Replication
Themutation responsible for ID in the first family reported
as linked to the MRX3 locus remained unsolved for a long
time after the initial linkage analysis of 1991. A targeted
massive resequencing of the genomic linkage interval
recently revealed a regulatory point mutation in a func-
tional binding site for the YY1 transcription factor in the
HCFC1 (host-cell factor C1) promoter; this mutation leads
to an upregulation of the gene’s expression in lymphoblas-
toid cells. The screening of extra unsolved XLID-affected
families identified an additional missense mutation
(c.674G>A [p.Ser225Asn]) segregating with the disease.55, 2013
Both mutations are absent from EVS, and other unique
missense variants were also described in a female with
schizophrenia and a boy with ASD.87 However, because
HCFC1 encodes a large protein of 2,035 amino acids, the
probability of identifying a missense change is high (22
missense variants predicted to be possibly or probably
damaging are present in EVS). Additional evidence would
therefore be useful for definitely confirming the implica-
tion of HCFC1 in ID.
HUWE1: Likely
HUWE1 (Hect, UBA, and WWE domains-containing pro-
tein 1) encodes a very large protein (4,375 amino acids)
with an E3 ubiquitin ligase function. Array comparative
genomic hybridization analysis initially detected duplica-
tions of HUWE1 and HSD17B10, both of which showed
overexpression in affected probands in six families afflicted
with predominantly nonsyndromic XLID; two of these
families were large XLID-affected families.61 Four similar
cases were reported in an independent replication
study.60 A further CNV analysis showed that de novo du-
plications covering HUWE1 alone were also associated
with simplex cases of ID, indicating that increased expres-
sion of this gene is deleterious.62 In the initial study, three
different missense mutations affecting highly conserved
residues and cosegregating with the ID status were id-
entified in three unrelated XLID-affected families
(c.12037C>T [p.Arg4013Trp] in a large Australian family
[LOD score ¼ 3.31]88 and c.8942G>A [p.Arg2981His] and
c.12559C>T [p.Arg4187Cys] in two smaller families; all
three mutations were absent from 750 controls). More
recently, a de novo missense variant (c.2849T>A [p.Va-
l950Asp]) was observed in one ASD male but was absent
in his less severely affected brother, suggesting either a
different etiology or complex inheritance.63 None of these
variants is present in EVS. Functional studies, notably in
mouse models, indicate that HUWE1 plays a role in the
control of neurogenesis in the developing brain via the
N-Myc pathway.89–91 In mice, targeted inactivation of
Huwe1 in the CNS or only in cerebellar granule neuron pre-
cursors and radial glia resulted in high neonatal lethality,
which could explain the absence of truncating mutations
reported in individuals.89,90 All these observations further
support the role of mutations in HUWE1 in XLID. Howev-
er, one should be very cautious in ascribing a pathogenic
role to a HUWE1 missense change identified in an individ-
ual with ID because 21 different such variants were
observed in males in the NHLBI cohort (ten of these vari-
ants are qualified as possibly or probably damaging); this
number is consistent with the large target size of the pro-
tein-coding sequence.
dN/dS Ratio Distribution among the Genes Involved
in XLID
The latest publication on EVS data reported a total of
285,960 nonsynonymous and 188,975 silent variants on
2,440 exomes.16 Interestingly, compared to the fullThe Amergenome, genes implicated in XLID tend to accumulate
fewer nonsynonymous variants (nonsynonymous ¼
2,623; silent ¼ 2,195; p ¼ 0.04). In order to estimate the
evolutionary pressure exerted on those different genes,
we used EVS to compute an intrahuman dN/dS ratio,
which we calculated by using DnaSP.92 For this ratio, the
number of nonsynonymous variants observed in EVS
over the number of total putative nonsynonymous posi-
tions in the studied transcript is divided by the analogous
ratio for synonymous variants (Table S5). Accordingly, a
strong selection pressure is expected to engender a low
dN/dS ratio, and a truly associated gene can be expected
to have such a low ratio in a general population. In
contrast, genes that show a high dN/dS ratio are less likely
to be disease related, especially if the disease affects fitness.
We generated box plots of the dN/dS ratios for the 104
selected genes with supposed involvement in XLID accord-
ing to the category we classed them into (Figure S1). Inter-
estingly, the mean dN/dS ratios for the ten genes in which
mutations associated with ID are questioned was signifi-
cantly higher than that for the validated genes (m ¼
0.604 5 0.150 versus m ¼ 0.359 5 0.255; Student’s t test
p ¼ 0.0004). Conversely, no significant difference was
observed between the validated and the ‘‘awaiting replica-
tion’’ pools (m ¼ 0.427 5 0.259, Student’s t test p ¼ 0.35)
that might contain genes with either real or no implication
in ID. Among the 11 genes with a high dN/dS ratio above
the 90th percentile (0.723; Table S5), four belong to the
‘‘questionable’’ class (AGTR2, ZNF674, SRPX2, and NXF5)
and three are considered to be ‘‘awaiting replication’’
(CCDC22, KLF8, and SHROOM4).
Discussion
This work demonstrates that among the 100 genes
described in the past as involved in XLID (on the basis of
available data sets and sequencing technologies), at least
10 (10%) appear doubtful and 15 others should be consid-
ered with caution until validation by replication studies.
The involvement in ID of two of these genes, AGTR2 and
ZNF674, was already questioned in specific publications
that were seldom cited.22,34 Curiously, some fully validated
genes are missing from several XLID diagnostic panels
(NSDHL [MIM 300275], MBTPS2 [MIM 300294], SLC6A8
[MIM 300036], etc., Figure 1), whereas others that have
been described in only a few studies and whose implica-
tion in ID is not fully convincing are systematically
included (AGTR2, MAGT1, ZNF41, and SRPX2). This
work also highlights that even in a well-known ID-associ-
ated gene, the pathogenicity of a novel nonsynonymous
variant should be inferred with caution given that some re-
ported nonsynonymous ‘‘mutations’’ inNDUFA1, TSPAN7,
or PTCHD1 are likely to be nonpathogenic (or at least not
fully penetrant), and this is of particular relevance for diag-
nostic applications (see also HUWE1 section).93
The number of genes involved in ID when mutated is
rapidly growing as a result of the exome-sequencing anal-
ysis of cohorts of affected individuals.12–14 Although theican Journal of Human Genetics 93, 368–383, August 8, 2013 377
Table 2. Proposed Guidelines for the Assessment of a Variant or a Gene Potentially Involved in ID or in Another Rare or Genetically
Heterogeneous Diseasea
X-Linked or Dominant Form Recessive Formb
Involvement of a Variant in a Disease
Supports not found in any malec or individual of the GP found at an allele frequency %
ﬃﬃ
i
p
segregates with the disease in the familyc
appears de novo in a simplex case
Inconclusive found in one malec or individual of the GP
Does not support found in more than one malec or individual of the GP found in GP at an allele frequency >
ﬃﬃ
i
p
Association between a Gene and a Disease
Supports additional candidate variant(s) in unrelated individuals with similar specific phenotype
If candidate mutation(s) ¼ protein truncation(s):
- no truncating variant is reported in malesc or individuals of the GP
-
If candidate mutation(s) ¼ missense(s):
- a low level of missense mutations predicted to be damaging is
reported in malesa or individuals of the GP
-
Inconclusive If candidate mutation(s) ¼ protein truncation(s):
- one truncating variant in one malec or individual of the GP
- truncating variants in the GP affect only the last amino acids or one
of several functional isoform(s)
-
Does not support If candidate mutation(s) ¼ protein truncation(s):
- several truncating variants in malesc or individuals of the GP
homozygous truncating or damaging variants are
reported in individuals of the GP
If candidate mutation(s) ¼ missense(s):
- high level of missenses in the GP (high dN/dS ratio, e.g., >0.7)
truncating or damaging variants are reported in the
GP at allele frequency >
ﬃﬃ
i
p
The ID example (incidence ¼ 2%): we do not expect one mutation responsible for more than 0.1% of ID cases, so i ¼ 0.02 3 0.001 ¼ 1 / 50,000 in the GP.
Therefore, the variation should not be found at a frequency>
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=50;000
p ¼ 0.0045, meaning nomore than 38 times in 8,600 European American chromosomes.
Most true mutations should be even rarer given mutation heterogeneity at a given locus; for instance, the most frequent mutation in phenylketonuria (c.1222C>T
[p.Arg408Trp]) is found 15 times in 8,600 European American chromosomes. The following abbreviations are used: GP, general population (e.g., EVS); and i,
estimated disease incidence that can be caused by mutations in a single gene after postulated nonallelic genetic heterogeneity is taken into account.
aFor a phenotype not enriched in the cohort used as a GP.
bCaution: geographic origin of the GP should match that of individuals with the candidate mutation.
cFor an X-linked disease.discovery of mutations in additional genes represents an
important step for further understanding the underlying
genetics of ID, there is a clear need for replication studies
to validate these findings (such as the recent work by
O’Roak et al.).94 Recently, RAB40AL (MIM 300405), not
included in our list, was found to be associated with
Martin-Probst syndrome (MPS [MIM 300519]), a disorder
characterized by deafness, cognitive impairment, short
stature, and distinct craniofacial dysmorphisms, with
the identification (by parallel whole-genome, whole-
exome, and X-exome sequencing) of a 2 nt substitution
(c.176_177AC>GA) leading to a missense change (p.As-
p59Gly) shown to disrupt protein localization.95 However,
this variation is present in two males in the EVS popula-
tion. Also, a few months after this initial publication, Iqbal
et al. reported it in four other ID-affected families; howev-
er, it was not related to the disease in at least three of the
families, questioning the involvement of RAB40AL in the
MPS phenotype.96 Some other recent publications of
exome sequencing in ID and ASD simplex cases identified
de novo truncating variants suggested by the authors to be
most likely involved in autosomal-dominant ID or ASD in
genes not previously associated with these diseases. How-378 The American Journal of Human Genetics 93, 368–383, August 8ever, for ADAM33, which was initially considered a candi-
date gene for dominant forms of ASD after a de novo trun-
cating mutation was identified in an ASD proband, three
nonsense variants and two splice variants were reported
in a total of five carrier individuals from the NHLBI
cohort.97 Similarly, six nonsense and three splice variants
were detected in a total of 11 carriers in ACACB, which
was also proposed as a likely candidate for dominant
ASD.98 This illustrates that an analysis similar to ours
should be performed on all proposed autosomal genes for
both dominant and recessive forms of ID.
We believe that this approach should be extended to
other Mendelian diseases with high genetic heterogeneity,
but the way to assimilate the NHLBI data has to be adapted
carefully and specifically for each disease by the integra-
tion of both its frequency and proposed transmission
mode (see Table 2). While this work was being completed,
a thorough similar review of mutations previously associ-
ated with cardiomyopathy revealed the presence of about
15% of them in EVS, showing a cumulative frequency
inconsistent with an implication in monogenic forms of
the disease.99 However, the NHLBI cohort cannot really
be considered a control cohort with respect to, 2013
cardiomyopathies or other cardiac diseases given that
many individuals were recruited through the NHLBI
because of cardiac phenotypes.
Because data from projects such as the NHLBI Exome
Sequencing Project are available, one should check for
the absence of each candidate mutation, especially if it is
a missense change. In the case of a novel candidate muta-
tion in a gene never associated with a disease, one should
also analyze other information provided by EVS, such as
the presence of truncating variants and the dN/dS ratio.
Indeed, this ratio is a good indicator of the selection pres-
sure exerted on a particular gene, and if the candidate mu-
tation results in a missense change, one should remember
that there is a higher likelihood of identifying a neutral
nonsynonymous change in a gene with a high dN/dS ratio.
However, one important limitation of the EVS is the
impossibility of going back to the cognitive or neurologic
phenotype of individuals in whom rare potentially patho-
genic variants were detected. Similarly to existing CNV da-
tabases, such as Decipher,100 a public database of rare
exome variants linked to some phenotypic descriptions
would be warranted, especially given the overwhelming
amount of such sequencing information that is currently
being generated in research and that will be soon engen-
dered for diagnostic purposes of ID and autism.Supplemental Data
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